Former Employee and patent attorney Dr Moshe Treitel sent me a link to an article in the Jerusalem Post that describes a technology that Teva has developed for better diagnosing. See here for more details.
Quoting Judy Itzkovich’s article:
“As the average Israeli 65 years and older now takes seven different medications for chronic illness, the danger of drug conflicts and complications is high.
In this country, adverse drug reactions (ADRs) are responsible for 4.1 percent of all hospital admissions, while it is 5.7% in Germany, 6.5% in Britain and a whopping 12% in Australia.”
The system, developed by Dr Ronni Shiloh, attempts to minimize adverse drug-drug interactions and to correct doses for specific patients by providing the doctor with a simple graphic interface or GUI on a smartphone or tablet, that summarizes a wealth of medical information in a simple and easy to comprehend graphical interface.
Drug interactions are a major cause of complications, particularly in the elderly. This product may save unneccessary hospitalization and expensive testing, to the benefit of patients, health funds and the Health Ministry alike.
גילוי נאות – Full Disclosure
I drafted the patent application for Teva and am prosecuting it in various jurisdictions. They out-sourced to me, since despite being Israel’s largest IP firm (that’s Teva, not IP Factor!), their extensive in-house patent capability is mostly pharmaceutical and molecular biology, whereas this is a computer based system.